Hematology

Sana Biotechnology also plans to submit another IND for the same indications for a CD22-targeted CAR T later in 2022.

Cilta-cel demonstrated a significant improvement in progression-free survival over standards of care.

Review top news and interview highlights from the week ending January 27, 2023.